Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastic Medullary Carcinoma of Thyroid With Functional Imaging Correlation.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Sunitinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 25 Apr 2017 Biomarkers information updated
- 21 Nov 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 06 Dec 2011 Planned end date changed from 1 Jul 2011 to 1 Jul 2012 as reported by ClinicalTrials.gov.